Intravenous Ketamine Alleviates Pain in a Rheumatoid Arthritis Patient With Comorbid Fibromyalgia

Ashraf F. Hanna\textsuperscript{a, b}, Bishoy Abrahama, Andrew Hannaa, Micheal McKenna, Adam J. Smith \textsuperscript{a}

Abstract

A 49-year-old woman with rheumatoid arthritis (RA) and comorbid fibromyalgia presented to the clinic in extreme pain, described to be a 10 on an 11-point pain intensity numerical rating scale (PI-NRS). Because the patient also met the diagnostic criteria for fibromyalgia and conventional medications did not achieve adequate pain control for either condition, the off-label use of intravenous (IV) ketamine was presented as an alternative therapeutic option. The patient underwent 10 consecutive IV infusion sessions with increasing doses of ketamine hydrochloride without any complications. Following the 10th infusion, the patient reported that her pain was virtually non-existent (PI-NRS 0-1).

Keywords: IV ketamine; Chronic pain; Pain management; Autoimmune disorders; NMDA antagonist

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to stiffness, pain and swelling of the joints. Management goals include preventing further joint damage and disability, which requires arresting disease progress. To that end, numerous pharmacotherapies are currently available that target pathogenic cytokines such as TNF-\(\alpha\), IL-1\(\beta\), or IL-6 [1]. These include five main classes of drugs: analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, non-biologic and biologic disease-modifying anti-rheumatic drugs [2]. Unfortunately, many patients have a sub-optimal response to these drug options or experience medication-related side effects that necessitate exploring other options. Interestingly, patients with RA have been associated with an increased risk in developing fibromyalgia [3].

Fibromyalgia is a disorder with clinical manifestations that include widespread pain, tenderness, fatigue, sleep disturbance, and psychological distress [4]. It is commonly regarded as the “prototypical central sensitivity syndrome” [5]. While its etiology is not fully understood, fibromyalgia is thought to result from abnormal central pain processing and increased central sensitivity that results in intense, widespread pain. Fibromyalgia is diagnosed using the 2010 American College of Rheumatology (ACR) criteria [6]: 1) Widespread pain index (WPI) \(\geq 7\) and symptom severity (SS) scale score \(\geq 5\) or WPI \(3 - 6\) and SS scale score \(\geq 9\). 2) Symptoms have been present for at least 3 months. 3) The patient does not have a disorder that would otherwise explain the pain.

A recent epidemiological study characterized the prevalence of fibromyalgia among patients without pain, with regional pain, and with widespread pain [4]. Using the ACR criteria for fibromyalgia [6], the study found that the estimated prevalence of fibromyalgia was 2.0% for both sexes, 3.4% for women and 0.4% for men. Interestingly, RA is widely known to be more common in women with epidemiological data indicating that the sex ratio is somewhere between 2:1 and 3:1 [7]. Thus, fibromyalgia and RA are significant and prevalent health problems that disproportionately affect women.

Ketamine is a long-known, dissociative anesthetic that strongly antagonizes the N-methyl-D-aspartate (NMDA) receptor. Although this is its most well-known pharmacological action, emerging research has shown that ketamine produces effects that reach far beyond NMDA antagonism. A recent clinical study investigated the immune response in patients undergoing elective abdominal surgery was given intravenous (IV) ketamine or a saline placebo prior to induction of general anesthesia [8]. Interestingly, the group of patients that had received ketamine showed a significantly suppressed production of IL-6 (\(P < 0.01\)) compared to controls. Moreover, the ketamine group also produced less TNF-\(\alpha\) post-operation. Numerous clinical studies have shown that ketamine possesses significant analgesic properties [9-11]. Our own clinical experience using ketamine for treatment-refractory pain has been positive and we have previously reported long-term pain relief in a patient with fibromyalgia [12].

Given these immunomodulatory, anti-inflammatory, and analgesic effects of ketamine, it seems to have tremendous potential for treating severe cases of RA that do not respond to conservative treatment options. Recently, the effects of ketamine in a rat model of RA were investigated and it was found that ketamine significantly reduced arthritis severity as indicated by reduced joint swelling, reduced infiltration of inflammatory cells and reduced joint destruction in the acute

Manuscript submitted February 5, 2018, accepted February 13, 2018

\textsuperscript{a}Florida Spine Institute, Clearwater, FL, USA
\textsuperscript{b}Corresponding Author: Ashraf Hanna, Florida Spine Institute, 2250 Drew St., Clearwater, FL 33765, USA. Email: asmithphd@me.com

doi: https://doi.org/10.14740/jmc3017w
and chronic phase of arthritis [13]. Although these results were very promising, preclinical data do not always translate to the clinic and no clinical data were available for the use of ketamine in patients with RA.

The case report described herein will discuss the clinical course of a female patient with RA and comorbid fibromyalgia treated with IV ketamine.

**Case Report**

A 49-year-old woman was referred to the Florida Spine Institute (Clearwater, FL) by her rheumatologist after being diagnosed with seronegative erosive RA. Her diagnostic labs indicated that she had high levels of C-reactive protein but was negative for rheumatoid factor and anti-cyclitullinated peptide antibody. Under the care of her rheumatologist, her arthritis was refractory to several conventional treatment options including methotrexate, tocilizumab, abatacept, belimumab, apremilast, golimumab, and leflunomide. On January 27, 2016, her pain intensity was reported to be 10 on an 11-point pain intensity numerical rating scale (PI-NRS), where 0 is no pain and 10 is worst possible pain.

The patient described cervical bilateral symmetrical facetogenic pain and symmetric bilateral sacroiliac joint pain with stiffness in the mornings for more than 60 min. Moreover, she had symmetric muscular pain and met the diagnostic criteria for fibromyalgia established by the ACR [6]. Numerous conservative treatment approaches were tried including physical therapy for cervical and lumbar pain with mild and temporary relief. Trigger point injections and bilateral sacroiliac joint injections under fluoroscopy did not result in any significant pain relief. She also underwent cervical radiofrequency ablation with no relief from pain. Since other therapeutic options did not achieve adequate pain control, the off-label use of IV ketamine was discussed with the patient. Because ketamine can exacerbate schizophrenia and abnormal liver function, patients should be screened for these conditions prior to starting ketamine. The patient was scheduled for IV ketamine therapy after clearing a psychiatric evaluation for schizophrenia and passing a liver function test.

The patient started a 10-day IV ketamine infusion protocol on August 22, 2016 at the Florida Spine Institute. The starting dose was 428 mg ketamine HCl in 100 mL of 0.9% sodium chloride. This was escalated to 856 mg for the second and third infusions and further escalated to 1063 mg for the remaining infusions. All doses were well tolerated and no unexpected adverse effects were observed.

The clinical course of this patient is illustrated in Figure 1. Following the first infusion session, the patient indicated that her pain intensity had fallen to 6 (PI-NRS). Following the last infusion, the patient indicated that her pain had been almost completely eliminated (PI-NRS 0 - 1). The patient also remarked that her RA symptoms had improved drastically and she was no longer experiencing joint pain and stiffness in the mornings. However, the patient returned for a 2-day booster infusion approximately 3 weeks later due to her pain levels returning to 40% of her pre-ketamine levels. Approximately 3 months after this booster infusion, the patient returned for another 2-day booster infusion with pain levels at 30-40% of her pre-ketamine levels. At the most recent follow-up visit (90 days since the last booster infusion), the patient reported that her pain levels were low (PI-NRS 2), an 80% improvement from her pre-ketamine levels.

**Discussion**

To our knowledge, this is the first report on the use of ketamine in a patient with RA. Immediately following the 10-day ketamine infusion protocol, the patient’s pain was alleviated completely but did eventually return to 20-40% of pre-ketamine levels necessitating additional 2-day booster infusions. It is possible that a take-home ketamine-containing drug product may more adequately maintain the results achieved immediately following the 10-day infusion. However, there are currently no FDA-approved take-home ketamine products that can be prescribed. Overall, the patient was satisfied with the treatment outcome and experienced no adverse events. Because repeat exposures to ketamine have been associated with hepatotoxicity, regular blood tests are merited to monitor the patient’s liver enzymes (alanine transaminase, alkaline phosphatase, aspartate transaminase, and γ-glutamyl transferase).


References


Conflict of Interest

The authors declare no conflict of interest.

Abbreviations

RA: rheumatoid arthritis; IV: intravenous; FDA: United States Food and Drug Administration; PI-NRS: pain intensity numerical rating scale; NSAIDs: non-steroidal anti-inflammatories; ACR: American College of Rheumatology; WPI: widespread pain index; SS: symptom severity; NMDA: N-methyl-D-aspartate

Conclusion

Conclusions derived from the clinical evidence described in this case report are limited in that it involves the experience of only one patient. Moreover, as a case report, there was no placebo control. Since ketamine is already an FDA-approved drug with decades of safe human experience, there is considerably less risk for pharmaceutical companies willing to pursue new indications with patient-friendly routes of administration. We are hopeful that future adequately powered and placebo-controlled clinical trials may confirm that ketamine is safe and effective for the treatment of autoimmune diseases such as RA.